Form 4: Intra-Cellular Therapies Executive Receives Stock Grant

Mark Neumann, EVP and Chief Commercial Officer of Intra-Cellular Therapies, Inc., was granted 26,227 restricted stock units on March 1, 2024.

Summary

• On March 1, 2024, Mark Neumann, the EVP and Chief Commercial Officer of Intra-Cellular Therapies, Inc., received a grant of 26,227 restricted stock units (RSUs).
• These RSUs represent a contingent right to receive one share of common stock per unit.
• The RSUs will vest in three equal annual installments, starting on the first anniversary of the grant date.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing regarding executive compensation, which is neither particularly positive nor negative. It reflects standard business practice.

Positives

• The grant of restricted stock units aligns the executive's interests with those of the shareholders.
• Vesting over three years encourages long-term commitment from the executive.

Future Outlook

The executive's compensation is tied to the company's performance over the next three years due to the vesting schedule of the RSUs.

Industry Context

Stock grants are a common form of executive compensation in the pharmaceutical industry, used to incentivize performance and retain key personnel.

Stakeholder Impact

• Shareholders may view the stock grant as a positive incentive for the executive to drive company performance.
• Employees may see the grant as a sign of the company's commitment to its leadership.

Key Dates